Core Insights - The company is expanding the indications for its major products, including "Zhixinxuan" and "Jindi," to enhance market competitiveness and meet diverse patient needs [1] - The company's revenue and net profit for the first half of 2025 have decreased year-on-year, primarily due to a decline in sales of respiratory and anti-infection products, coupled with a shift in revenue mix towards lower-margin health consumer products [1] - The company is actively seeking acquisition opportunities to align with its strategic focus on traditional Chinese medicine and health, evaluating potential targets based on strategic fit, revenue potential, and compatibility with existing product lines [2] Financial Performance - The company reported a year-on-year decline in both operating revenue and net profit for the first half of 2025 [1] - The decrease in net profit was more significant than the decline in operating revenue due to a higher proportion of lower-margin products in the revenue mix [1] Acquisition Strategy - The company is enhancing its business development (BD) system to identify and acquire potential high-value products that align with its strategic direction [2] - Recent approvals for new products, such as the throat lozenge, are part of a strategy to enrich the product pipeline in the cold and throat category [2] - Ongoing discussions for potential acquisition targets are in progress, although previous projects have not yet materialized due to various reasons [2]